U.S. Markets closed

Lixte Biotechnology Holdings, Inc. (LIXT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.5999+0.0429 (+7.70%)
At close: 03:30PM EDT
0.5999 0.00 (0.00%)
After hours: 05:15PM EDT

Lixte Biotechnology Holdings, Inc.

680 East Colorado Boulevard
Suite 180
Pasadena, CA 91101
United States
631 830 7092

Full Time Employees3

Key Executives

NameTitlePayExercisedYear Born
Dr. John S. KovachFounder, Pres, CEO, Chief Scientific Officer & Chairman250kN/A1937
Mr. Robert Neal WeingartenVP & CFO156.67kN/A1952
Mr. Eric J. Forman J.D.Chief Admin. Officer156.67kN/A1979
Dr. James S. Miser M.D.Chief Medical Officer166.67kN/A1947
Mr. Gil N. Schwartzberg Esq., J.D.Independent Director14.56kN/A1942
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. The company was founded in 2005 and is based in Pasadena, California.

Corporate Governance

Lixte Biotechnology Holdings, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.